课题基金 / 基金详情

SEROTONERGIC MECHANISMS AND SELF-INJURIOUS BEHAVIOR

SEROTONERGIC MECHANISMS AND SELF-INJURIOUS BEHAVIOR
血清素能机制和自残行为
批准号:
3088908
负责人:
Bryan H King
金额:
$14.47万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-02-01 至 1996-01-31

项目摘要

项目成果

Bryan H King的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
"Self-injurious behavior" (SIB) refers to acts which are usually highly repetitive in character and which result in direct physical damage to the individual. SIB is a significant problem. At the Lanterman State Developmental Center in Pomona, California, SIB occurs daily in fully 14% of the resident population. SIB restricts the affected person from educational and social opportunities and can restrict placement to institutional settings. It is estimated that the annual care for a single individual with SIB approaches $100,000 while cost to the nation of the twenty thousand afflicted individuals exceeded three billion dollars in 1988. We will focus on the pathogenesis and treatment of self-injurious behavior in the developmentally disabled. With a two-fold aim of establishing and examining appropriate models of this behavior, and of careful clinical study of a large population of developmentally disabled individuals who engage in frequent SIB. The hypothesis to be tested can be summarized: Pre-Clinical Studies: The serotonin agonist m-chlorophenylpiperazine (mCPP) will increase rat plasma adrenocorticoptopic hormone (ACTH). This neuroendocrine response will be differentially modified by the chronic administration of serotonergic agonists and antagonists. Pharmacological or surgical induction of self-injury will also modify the neuroendocrine response to mCPP. SIB in these models will be altered or acutely prevented by short-term treatment with some 5-HT antagonists; however, long-term treatment with 5-HT agonists, particularly buspirone or mCPP, or with re-uptake blockers like fluoxetine or sertraline will also attenuate SIB in these systems. Clinical studies: Some patients with self-injurious behavior will demonstrate functional differences in response to specific neuroendocrine challenge when compared to developmentally disabled and to normal controls. Following chronic treatment with the serotonergic agents buspirone and fluoxetine, the functional response to these neuroendocrine challenges will be altered both in normal volunteers and in a subgroup of individuals with SIB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDD
  • 批准号:
    7889283
  • 项目类别:
  • 资助金额:
    $32.51万
  • 财政年份:
    2010
  • 负责人:
    Bryan H King
  • 依托单位:
2/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDD
  • 批准号:
    8235066
  • 项目类别:
  • 资助金额:
    $17.18万
  • 财政年份:
    2010
  • 负责人:
    Bryan H King
  • 依托单位:
2/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDD
  • 批准号:
    8098700
  • 项目类别:
  • 资助金额:
    $31.17万
  • 财政年份:
    2010
  • 负责人:
    Bryan H King
  • 依托单位:
TREATMENT OF AFFECTIVE DISTURBANCE IN CHILDREN WITH AUTISM
  • 批准号:
    7560764
  • 项目类别:
  • 资助金额:
    $25.87万
  • 财政年份:
    2007
  • 负责人:
    Bryan H King
  • 依托单位:
海外基金